Hematin therapy in porphyric attacks.
We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favor able clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.
D006418:Heme / Q000031:analogs & derivatives*; D006427:Hemin / Q000627:therapeutic use*; D006801:Humans; D011164:Porphyrias / Q000188:drug therapy*
D006418:Heme; D006427:Hemin